Nicotine does not kill viruses. No published research has demonstrated that nicotine destroys viral particles, disrupts their structure, or directly stops them from replicating. In fact, the weight of evidence points in the opposite direction: nicotine generally makes your body more vulnerable to viral infections, not less.
This question gained traction during the early days of the COVID-19 pandemic, when a few researchers proposed that nicotine might block the virus from entering cells. That hypothesis has not held up. Here’s what the science actually shows.
Where the Idea Came From
In 2020, a French research team led by Jean-Pierre Changeux proposed that nicotine might interfere with SARS-CoV-2 by binding to the same type of receptor the virus uses to enter the body. The idea was that nicotine could essentially block the door. Some early, incomplete data from hospitals appeared to show that smokers were underrepresented among hospitalized COVID patients, which fueled speculation.
The hypothesis was tested directly. When researchers exposed lung cells to nicotine and then infected them with SARS-CoV-2, nicotine provided no protection whatsoever at any concentration tested. A study published in PLoS One tested nicotine at concentrations up to 65 times higher than what a smoker’s blood typically contains and found zero cytoprotective activity against the virus. The nicotine simply did not shield cells from infection.
Nicotine Actually Helps Some Viruses Get In
Rather than blocking viral entry, nicotine appears to open the door wider. The SARS-CoV-2 virus enters human cells by latching onto a protein called ACE2 on the cell surface. Nicotine increases the amount of ACE2 that lung cells produce. Research published in ERJ Open Research showed that exposing human lung cells to nicotine caused a rapid and significant increase in ACE2 at both the gene and protein level, peaking at 24 hours. More ACE2 on the surface of your lung cells means more entry points for the virus.
The same researchers found that this ACE2 increase translated directly into worse outcomes for the cells: higher viral replication and more cell damage. These effects were specifically triggered through a nicotine-sensitive receptor on the cell surface called the alpha-7 nicotinic acetylcholine receptor. When that receptor was blocked, the ACE2 increase didn’t happen, confirming nicotine was the driver.
How Nicotine Weakens Your Viral Defenses
Your immune system fights viruses through a layered defense. Nicotine undermines several of those layers at once.
Macrophages, the immune cells responsible for engulfing and destroying pathogens, become less effective with nicotine exposure. One study found that nicotine reduced macrophage phagocytosis (their ability to “eat” invaders) by about 15%. It also decreased the number of scavenging receptors on each macrophage, cutting their pathogen-detecting equipment by more than half compared to untreated cells. At the same time, nicotine suppressed the production of key signaling molecules that coordinate the immune response, including several that recruit other immune cells to the site of infection.
At higher concentrations, particularly at levels typical in regular smokers, nicotine shifts the immune system toward an anti-inflammatory state that sounds beneficial but is actually counterproductive during an active infection. Your body needs inflammation to fight viruses. Nicotine suppresses the production of interferon-gamma, a critical molecule for antiviral defense, while boosting anti-inflammatory signals. One review noted that immune suppression can be up to ten times greater at concentrations typical in smokers compared to lower exposures.
What Happened in Clinical Trials
The nicotine hypothesis was put to the most rigorous test possible: a randomized, double-blind, placebo-controlled trial. Conducted across 18 intensive care units in France, the study enrolled 218 non-smoking patients who were on ventilators for severe COVID-19 pneumonia. Half received nicotine patches (14 mg daily) and half received identical-looking placebo patches.
The result was unambiguous. Mortality at 28 days was 28% in both groups. Nicotine provided no benefit for survival, time on the ventilator, organ failure, or any other measured outcome. The researchers concluded bluntly: “There is no indication to use nicotine in this situation.”
Nicotine and Influenza
The evidence isn’t limited to coronaviruses. Research on influenza paints a similar picture. Nasal cells taken from smokers supported six times more flu virus replication than cells from nonsmokers. Lung cells exposed to cigarette smoke in the lab allowed tenfold higher replication of H1N1 influenza compared to unexposed cells. In animal studies, smoke-exposed mice infected with influenza had worse weight loss, more lung scarring, and higher death rates than unexposed mice.
Nicotine exposure also undermines your body’s ability to build lasting protection. While blood-level antibodies against influenza remain roughly the same in smokers, the mucosal antibodies in the airways (IgA, the first line of defense where the virus actually lands) are lower. This means even if your overall immune response looks normal on a blood test, the defenses right where the virus enters are weakened.
Pure Nicotine vs. Tobacco Smoke
Some researchers have argued that pure nicotine should be evaluated separately from cigarette smoke, since smoke contains thousands of toxic compounds beyond nicotine. This is a fair scientific point, and the two do have some different effects. Nicotine on its own does activate anti-inflammatory pathways through the alpha-7 receptor, and this property has shown genuine therapeutic value in conditions like ulcerative colitis, where excessive inflammation is the core problem.
But for viral infections, this anti-inflammatory effect works against you. The cell-level studies that showed nicotine increasing ACE2 and boosting viral replication used pure nicotine, not cigarette smoke. The clinical trial used nicotine patches, not cigarettes. And neither showed antiviral benefit. Nicotine in its isolated form still increased viral entry points on lung cells and still suppressed immune function. The harmful effects on viral defense are not just a smoke problem.
The Bottom Line on Nicotine and Viruses
Nicotine does not kill, inactivate, or inhibit viruses at any concentration that has been tested in cells or in humans. It increases the receptors that certain viruses use to enter your cells, reduces the ability of immune cells to detect and destroy pathogens, and suppresses the inflammatory signals your body needs to mount an effective antiviral response. A well-designed clinical trial found no survival benefit from nicotine patches in severe COVID-19. Population-level data on influenza and other respiratory viruses consistently shows that nicotine exposure increases infection risk and severity rather than reducing it.